ImmuCell Corp Files 8-K with Financial Updates
Ticker: ICCC · Form: 8-K · Filed: Jul 9, 2024 · CIK: 811641
| Field | Detail |
|---|---|
| Company | Immucell Corp /De/ (ICCC) |
| Form Type | 8-K |
| Filed Date | Jul 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
ImmuCell Corp dropped an 8-K on 7/9 with financial results. Check it out.
AI Summary
On July 9, 2024, ImmuCell Corporation filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits related to the company's performance. ImmuCell Corporation is incorporated in Delaware and is headquartered in Portland, Maine.
Why It Matters
This 8-K filing provides investors with crucial updates on ImmuCell Corporation's financial condition and operational results, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate or significant new risks.
Key Players & Entities
- ImmuCell Corporation (company) — Registrant
- July 9, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- Portland, Maine (location) — Principal executive offices
- 207-878-2770 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this Form 8-K filing for ImmuCell Corporation?
The primary purpose of this Form 8-K filing is to report the Results of Operations and Financial Condition, along with Financial Statements and Exhibits, as of July 9, 2024.
When was ImmuCell Corporation incorporated, and where is its principal executive office located?
ImmuCell Corporation was incorporated in Delaware and its principal executive offices are located at 56 Evergreen Drive, Portland, Maine, 04103.
What is the Commission File Number and IRS Employer Identification Number for ImmuCell Corporation?
The Commission File Number for ImmuCell Corporation is 001-12934, and its IRS Employer Identification No. is 01-0382980.
What is the SIC code for ImmuCell Corporation?
The Standard Industrial Classification (SIC) code for ImmuCell Corporation is 2835, which corresponds to IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
What is the fiscal year end for ImmuCell Corporation?
The fiscal year end for ImmuCell Corporation is December 31 (1231).
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-07-09 16:05:09
Key Financial Figures
- $0.10 — nge on which registered Common Stock, $0.10 par value per share ICCC The NASDAQ
Filing Documents
- ea0209162-8k_immucell.htm (8-K) — 26KB
- ea020916201ex99-1_immucell.htm (EX-99.1) — 20KB
- 0001213900-24-060121.txt ( ) — 219KB
- iccc-20240709.xsd (EX-101.SCH) — 3KB
- iccc-20240709_lab.xml (EX-101.LAB) — 33KB
- iccc-20240709_pre.xml (EX-101.PRE) — 22KB
- ea0209162-8k_immucell_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On July 9, 2024 ImmuCell Corporation (the "Company") issued a press release announcing its preliminary, unaudited product sales for the three-month and six-month periods ended June 30, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated July 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: July 9, 2024 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief Executive Officer and Principal Financial Officer 2 Exhibit Index Exhibit No. Description 99.1 Press Release of ImmuCell Corporation dated July 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3